These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34858891)

  • 1. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.
    Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL
    Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
    Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain.
    Guerra I; Algaba A; Jiménez L; Mar Aller M; Garza D; Bonillo D; Molina Esteban LM; Bermejo F
    Inflamm Bowel Dis; 2021 Jan; 27(1):25-33. PubMed ID: 32830267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
    Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
    Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.
    Burke KE; Kochar B; Allegretti JR; Winter RW; Lochhead P; Khalili H; Colizzo FP; Hamilton MJ; Chan WW; Ananthakrishnan AN
    Inflamm Bowel Dis; 2021 Jan; 27(2):155-161. PubMed ID: 33089863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease.
    Sahyoun LC; Fetene J; McMillan C; Protiva P; Al Bawardy B; Gaidos JKJ; Proctor D
    Dig Dis Sci; 2024 May; 69(5):1654-1660. PubMed ID: 38466459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 in IBD: The experience of a single tertiary IBD center.
    Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
    Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
    Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
    Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.
    Taxonera C; Sagastagoitia I; Alba C; Mañas N; Olivares D; Rey E
    Aliment Pharmacol Ther; 2020 Jul; 52(2):276-283. PubMed ID: 32359205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.
    Card TR; Nakafero G; Grainge MJ; Mallen CD; Van-Tam JSN; Williams HC; Abhishek A
    Am J Gastroenterol; 2023 Aug; 118(8):1388-1394. PubMed ID: 36826512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting.
    Creemers RH; Rezazadeh Ardabili A; Jonkers DM; Leers MPG; Romberg-Camps MJ; Pierik MJ; van Bodegraven AA
    PLoS One; 2021; 16(10):e0258271. PubMed ID: 34610041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.
    Derikx LAAP; Lantinga MA; de Jong DJ; van Dop WA; Creemers RH; Römkens TEH; Jansen JM; Mahmmod N; West RL; Tan ACITL; Bodelier AGL; Gorter MHP; Boekema PJ; Halet ERC; Horjus CS; van Dijk MA; Hirdes MMC; Epping Stippel LSM; Jharap B; Lutgens MWMD; Russel MG; Gilissen LPL; Nauta S; van Bodegraven AA; Hoentjen F
    J Crohns Colitis; 2021 Apr; 15(4):529-539. PubMed ID: 33079178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
    Lin S; Lau LH; Chanchlani N; Kennedy NA; Ng SC
    Gut; 2022 Jul; 71(7):1426-1439. PubMed ID: 35477864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.
    Scucchi L; Neri B; Sarmati L; Mossa M; Sena G; Massoud R; Petruzziello C; Musumeci M; Marafini I; Calabrese E; Lolli E; Bernardini S; Andreoni M; Monteleone G; Biancone L
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2418-2424. PubMed ID: 33755981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
    Khan N; Mahmud N
    Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
    Khan N; Mahmud N; Trivedi C; Reinisch W; Lewis JD
    Gut; 2021 Sep; 70(9):1657-1664. PubMed ID: 33753416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic.
    El Ouali S; Rubin DT; Cohen BL; Regueiro MD; Rieder F
    Curr Opin Gastroenterol; 2021 Jul; 37(4):313-319. PubMed ID: 33859104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.